中国组织工程研究 ›› 2024, Vol. 28 ›› Issue (20): 3272-3280.doi: 10.12307/2024.291
• 组织构建综述 tissue construction review • 上一篇
汪饶开卷1,2,赵立星1,2,3
收稿日期:
2023-03-24
接受日期:
2023-05-11
出版日期:
2024-07-18
发布日期:
2023-09-11
通讯作者:
赵立星,医学博士,副教授,副主任医师,硕士生导师,口腔疾病研究国家重点实验室/国家口腔疾病临床研究中心,四川省成都市 610041;四川大学华西口腔医学院,四川省成都市 610041;四川大学华西口腔医院正畸科,四川省成都市 610041
作者简介:
汪饶开卷,女,1997年生,汉族,四川大学华西口腔医学院在读硕士,主要从事高分子复合材料优化骨组织工程的研究。
基金资助:
Wang Raokaijuan1, 2, Zhao Lixing1, 2, 3
Received:
2023-03-24
Accepted:
2023-05-11
Online:
2024-07-18
Published:
2023-09-11
Contact:
Zhao Lixing, MD, Associate professor, Associate chief physician, Master’s supervisor, State Key Laboratory of Oral Diseases/National Clinical Research Center for Oral Diseases, Chengdu 610041, Sichuan Province, China; West China School of Stomatology Sichuan University, Chengdu 610041, Sichuan Province, China; Department of Orthodontics, West China School of Somatology, Sichuan University, Chengdu 610041, Sichuan Province, China
About author:
Wang Raokaijuan, Master candidate, State Key Laboratory of Oral Diseases/National Clinical Research Center for Oral Diseases, Chengdu 610041, Sichuan Province, China; West China School of Stomatology Sichuan University, Chengdu 610041, Sichuan Province, China
Supported by:
摘要:
文题释义:
去铁胺:是一种被美国食品和药物管理局批准的铁络合剂,属羟肟酸络合剂。在体内,去铁胺的羟肟酸基团对三价铁离子具有高亲和力并形成水溶性铁胺复合物后主要由尿排出,常用于铁超载或铁中毒的临床治疗。
背景:除了铁络合作用外,去铁胺还被认为是一种有效的低氧模拟剂及缺氧诱导因子1α稳定剂,近年的基础及临床研究中去铁胺也表现出良好的骨再生效应。去铁胺溶液或负载去铁胺的生物支架被局部应用于骨组织工程中,其对骨再生的促进涉及多种功能特性及分子机制,但尚未完全明确,且其在骨再生中的研究进展缺乏有效总结。
目的:对去铁胺应用于骨再生的功能特性、优缺点及其在基础研究及临床实践中的进展进行综述,以期为后续相关研究提供参考及策略。结果与结论:①去铁胺能招募干细胞并调节干细胞功能,激活相关信号通路提高细胞的低氧适应能力,发挥抗炎抗氧化特性改善局部炎性环境,并通过偶联成骨-成血管及抑制骨吸收来促进骨再生。②相较于传统骨组织工程中加载的生长因子或多肽,去铁胺作为小分子药物具有独特的优势,同时也存在毒性反应及应用局限,因此优化载药形式及剂量是必要的。③去铁胺独特的成血管-成骨偶联能力,在不同类型的骨损伤如骨折、骨坏死、牵张成骨、骨移植、口腔相关成骨及骨缺损中,因对骨愈合过程中血管生成的加强而更能适应和解决复杂多变的临床情况及个体差异下造成的骨修复困难;但同时也需要对去铁胺的应用方式及安全剂量加以对比和优化,利于其应用范围的扩大及临床价值的提升。
https://orcid.org/0000-0001-8185-7273(汪饶开卷);https://orcid.org/0000-0002-9870-6436(赵立星)
中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程
中图分类号:
汪饶开卷, 赵立星. 去铁胺在骨组织再生中的应用进展[J]. 中国组织工程研究, 2024, 28(20): 3272-3280.
Wang Raokaijuan, Zhao Lixing. Application of deferoxamine in bone tissue regeneration[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(20): 3272-3280.
[1] BAJBOUJ K, SHAFARIN J, HAMAD M. High-dose deferoxamine treatment disrupts intracellular iron homeostasis, reduces growth, and induces apoptosis in metastatic and nonmetastatic breast cancer cell lines. Technol Cancer Res Treat 2018;17:1533033818764470. [2] MOBARRA N, SHANAKI M, EHTERAM H, et al. A review on iron chelators in treatment of iron overload syndromes. Int J Hematol Oncol Stem Cell Res 2016;10(4):239-247. [3] KEBERLE H. The Biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 1964;119:758-768. [4] CUI HJ, HE HY, YANG AL, et al. Efficacy of deferoxamine in animal models of intracerebral hemorrhage: a systematic review and stratified meta-analysis. PLoS One 2015;10(5):e0127256. [5] BEEGLE J, LAKATOS K, KALOMOIRIS S, et al. Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo. Stem Cells 2015;33(6):1818-1828. [6] NOWAK-STEPNIOWSKA A, OSUCHOWSKA PN, FIEDOROWICZ H, et al. Insight in hypoxia-mimetic agents as potential tools for mesenchymal stem cell priming in regenerative medicine. Stem Cells Int. 2022;2022:8775591. [7] HWANG OK, NOH YW, HONG JT, et al. Hypoxia pretreatment promotes chondrocyte differentiation of human adipose-derived stem cells via vascular endothelial growth factor. Tissue Eng Regen Med 2020;17(3):335-350. [8] WANG L, JIA P, SHAN Y, et al. Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice. Mol Med Rep. 2017;16(5):6642-6649. [9] LIU C, TSAI AL, LI PC, et al. Endothelial differentiation of bone marrow mesenchyme stem cells applicable to hypoxia and increased migration through Akt and NFkappaB signals. Stem Cell Res Ther. 2017;8(1):29. [10] NGUYEN VT, CANCIANI B, CIRILLO F, et al. Effect of chemically induced hypoxia on osteogenic and angiogenic differentiation of bone marrow mesenchymal stem cells and human umbilical vein endothelial cells in direct coculture. Cells. 2020;9(3):757. [11] JIANG L, PENG WW, LI LF, et al. Effects of deferoxamine on the repair ability of dental pulp cells in vitro. J Endod. 2014;40(8):1100-1104. [12] LEE KE, MO S, LEE HS, et al. Deferoxamine reduces inflammation and osteoclastogenesis in avulsed teeth. Int J Mol Sci. 2021;22(15):8225. [13] MUSCARI C, GIORDANO E, BONAFE F, et al. Priming adult stem cells by hypoxic pretreatments for applications in regenerative medicine. J Biomed Sci. 2013;20(1):63. [14] KHOSHLAHNI N, SAGHA M, MIRZAPOUR T, et al. Iron depletion with deferoxamine protects bone marrow-derived mesenchymal stem cells against oxidative stress-induced apoptosis. Cell Stress Chaperones. 2020;25(6):1059-1069. [15] PEYVANDI AA, ABBASZADEH HA, ROOZBAHANY NA, et al. Deferoxamine promotes mesenchymal stem cell homing in noise-induced injured cochlea through PI3K/AKT pathway. Cell Prolif. 2018;51(2):e12434. [16] MATSUNAGA K, FUJISAWA K, TAKAMI T, et al. NUPR1 acts as a pro-survival factor in human bone marrow-derived mesenchymal stem cells and is induced by the hypoxia mimetic reagent deferoxamine. J Clin Biochem Nutr. 2019;64(3):209-216. [17] CHENG W, DING Z, ZHENG X, et al. Injectable hydrogel systems with multiple biophysical and biochemical cues for bone regeneration. Biomater Sci. 2020;8(9): 2537-2548. [18] MU S, GUO S, WANG X, et al. Effects of deferoxamine on the osteogenic differentiation of human periodontal ligament cells. Mol Med Rep. 2017;16(6):9579-9586. [19] CHUNG JH, KIM YS, NOH K, et al. Deferoxamine promotes osteoblastic differentiation in human periodontal ligament cells via the nuclear factor erythroid 2-related factor-mediated antioxidant signaling pathway. J Periodontal Res. 2014;49(5):563-573. [20] LIU GS, PESHAVARIYA HM, HIGUCHI M, et al. Pharmacological priming of adipose-derived stem cells for paracrine VEGF production with deferoxamine. J Tissue Eng Regen Med. 2016;10(3):E167-E176. [21] OSES C, OLIVARES B, EZQUER M, et al. Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: potential application in the treatment of diabetic neuropathy. PLoS One. 2017;12(5):e0178011. [22] CHEN H, JIA P, KANG H, et al. Upregulating hif-1alpha by hydrogel nanofibrous scaffolds for rapidly recruiting angiogenesis relative cells in diabetic wound. Adv Healthc Mater. 2016;5(8):907-918. [23] CHOI JH, LEE YB, JUNG J, et al. Hypoxia inducible factor-1alpha regulates the migration of bone marrow mesenchymal stem cells via integrin alpha 4. Stem Cells Int. 2016;2016:7932185. [24] ARMSTRONG A, MANDALA A, MALHOTRA M, et al. Canonical wnt signaling in the pathology of iron overload-induced oxidative stress and age-related diseases. Oxid Med Cell Longev. 2022;2022:7163326. [25] DAVIES MJ, DONKOR R, DUNSTER CA, et al. Desferrioxamine (Desferal) and superoxide free radicals. Formation of an enzyme-damaging nitroxide. Biochem J. 1987;246(3):725-729. [26] HARTLEY A, DAVIES M, RICE-EVANS C. Desferrioxamine as a lipid chain-breaking antioxidant in sickle erythrocyte membranes. FEBS Lett. 1990;264(1):145-148. [27] ZHU Y, CHANG B, PANG Y, et al. Advances in hypoxia-inducible factor-1alpha stabilizer deferoxamine in tissue engineering. Tissue Eng Part B Rev. 2023. doi:10.1089/ten.TEB.2022.0168. [28] WANG X, WU TT, JIANG L, et al. Deferoxamine-induced migration and odontoblast differentiation via ROS-dependent autophagy in dental pulp stem cells. Cell Physiol Biochem. 2017;43(6):2535-2547. [29] DI PAOLA A, TORTORA C, ARGENZIANO M, et al. Emerging roles of the iron chelators in inflammation. Int J Mol Sci. 2022;23(14):7977. [30] YAN HF, LIU ZY, GUAN ZA, et al. Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice. Endocr Connect. 2018;7(4):604-616. [31] DING Z, ZHANG Y, GUO P, et al. Injectable desferrioxamine-laden silk nanofiber hydrogels for accelerating diabetic wound healing. ACS Biomater Sci Eng. 2021;7(3):1147-1158. [32] ANDERSON GJ, FRAZER DM. Current understanding of iron homeostasis. Am J Clin Nutr. 2017;106(Suppl 6):1559S-1566S. [33] RAN Q, YU Y, CHEN W, et al. Deferoxamine loaded titania nanotubes substrates regulate osteogenic and angiogenic differentiation of MSCs via activation of HIF-1alpha signaling. Mater Sci Eng C Mater Biol Appl. 2018;91:44-54. [34] YAO Q, LIU Y, TAO J, et al. Hypoxia-mimicking nanofibrous scaffolds promote endogenous bone regeneration. ACS Appl Mater Interfaces. 2016;8(47):32450-32459. [35] LI H, LIAO L, HU Y, et al. Identification of type H vessels in mice mandibular condyle. J Dent Res. 2021;100(9):983-992. [36] JING X, DU T, YANG X, et al. Desferoxamine protects against glucocorticoid-induced osteonecrosis of the femoral head via activating HIF-1alpha expression. J Cell Physiol. 2020;235(12):9864-9875. [37] FARBERG AS, JING XL, MONSON LA, et al. Deferoxamine reverses radiation induced hypovascularity during bone regeneration and repair in the murine mandible. Bone. 2012;50(5):1184-1187. [38] KUSUMBE AP, RAMASAMY SK, ADAMS RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 2014;507(7492):323-328. [39] ZENG Y, HUANG C, DUAN D, et al. Injectable temperature-sensitive hydrogel system incorporating deferoxamine-loaded microspheres promotes H-type blood vessel-related bone repair of a critical size femoral defect. Acta Biomater. 2022;153:108-123. [40] XING W, POURTEYMOOR S, MOHAN S. Ascorbic acid regulates osterix expression in osteoblasts by activation of prolyl hydroxylase and ubiquitination-mediated proteosomal degradation pathway. Physiol Genomics. 2011;43(12):749-757. [41] CUI J, YU X, YU B, et al. Coaxially fabricated dual-drug loading electrospinning fibrous mat with programmed releasing behavior to boost vascularized bone regeneration. Adv Healthc Mater. 2022;11(16):e2200571. [42] BASCHANT U, RAUNER M, BALAIAN E, et al. Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors. Haematologica. 2016;101(12):1499-1507. [43] CHEN D, LI Y, ZHOU Z, et al. Synergistic inhibition of Wnt pathway by HIF-1alpha and osteoblast-specific transcription factor osterix (Osx) in osteoblasts. PLoS One. 2012;7(12):e52948. [44] YAO Q, LIU Y, SELVARATNAM B, et al. Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering. J Control Release. 2018;279:69-78. [45] ZHENG X, ZHANG X, WANG Y, et al. Hypoxia-mimicking 3D bioglass-nanoclay scaffolds promote endogenous bone regeneration. Bioact Mater. 2021;6(10):3485-3495. [46] HOSSEINPOUR S, FEKRAZAD R, ARANY PR, et al. Molecular impacts of photobiomodulation on bone regeneration: a systematic review. Prog Biophys Mol Biol. 2019;149:147-159. [47] LI H, LUO B, WEN W, et al. Deferoxamine immobilized poly(D,L-lactide) membrane via polydopamine adhesive coating: The influence on mouse embryo osteoblast precursor cells and human umbilical vein endothelial cells. Mater Sci Eng C Mater Biol Appl. 2017;70(Pt 1):701-709. [48] LIU Q, LI M, WANG S, et al. Recent advances of osterix transcription factor in osteoblast differentiation and bone formation. Front Cell Dev Biol. 2020;8:601224. [49] LUO C, XU W, TANG X, et al. Canonical Wnt signaling works downstream of iron overload to prevent ferroptosis from damaging osteoblast differentiation. Free Radic Biol Med. 2022;188:337-350. [50] BORRIELLO A, CALDARELLI I, SPERANZA MC, et al. Iron overload enhances human mesenchymal stromal cell growth and hampers matrix calcification. Biochim Biophys Acta. 2016;1860(6):1211-1223. [51] GATTERMANN N. Iron rusting in the mitochondria? Blood. 2016;128(15):1907-1908. [52] CALLAWAY DA, JIANG JX. Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab. 2015;33(4):359-370. [53] ZHANG J, HU W, DING C, et al. Deferoxamine inhibits iron-uptake stimulated osteoclast differentiation by suppressing electron transport chain and MAPKs signaling. Toxicol Lett. 2019;313:50-59. [54] KANG H, YAN Y, JIA P, et al. Desferrioxamine reduces ultrahigh-molecular-weight polyethylene-induced osteolysis by restraining inflammatory osteoclastogenesis via heme oxygenase-1. Cell Death Dis. 2016;7(10):e2435. [55] KNOWLES HJ, CLETON-JANSEN AM, KORSCHING E, et al. Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J. 2010;24(12):4648-4659. [56] YAN Y, CHEN H, ZHANG H, et al. Vascularized 3D printed scaffolds for promoting bone regeneration. Biomaterials. 2019;190-191:97-110. [57] HOLDEN P, NAIR LS. Deferoxamine: an angiogenic and antioxidant molecule for tissue regeneration. Tissue Eng Part B Rev. 2019;25(6):461-470. [58] SHI R, ZHANG J, NIU K, et al. Electrospun artificial periosteum loaded with DFO contributes to osteogenesis via the TGF-beta1/Smad2 pathway. Biomater Sci. 2021;9(6):2090-2102. [59] PFEIFFENBERGER M, DAMERAU A, PONOMAREV I, et al. Functional scaffold-free bone equivalents induce osteogenic and angiogenic processes in a human in vitro fracture hematoma model. J Bone Miner Res. 2021;36(6):1189-1201. [60] MATSUMOTO T, SATO S. Stimulating angiogenesis mitigates the unloading-induced reduction in osteogenesis in early-stage bone repair in rats. Physiol Rep. 2015;3(3):e12335. [61] LI J, FAN L, YU Z, et al. The effect of deferoxamine on angiogenesis and bone repair in steroid-induced osteonecrosis of rabbit femoral heads. Exp Biol Med (Maywood). 2015;240(2):273-280. [62] SHENG H, LAO Y, ZHANG S, et al. Combined pharmacotherapy with alendronate and desferoxamine regulate the bone resorption and bone regeneration for preventing glucocorticoids-induced osteonecrosis of the femoral head. Biomed Res Int. 2020; 2020:3120458. [63] MOMENI A, RAPP S, DONNEYS A, et al. Clinical use of deferoxamine in distraction osteogenesis of irradiated bone. J Craniofac Surg. 2016;27(4):880-882. [64] FARBERG AS, SARHADDI D, DONNEYS A, et al. Deferoxamine enhances bone regeneration in mandibular distraction osteogenesis. Plast Reconstr Surg. 2014; 133(3):666-671. [65] KALAY E, ERMUTLU C, YENIGUL AE, et al. Effect of bone morphogenic protein-2 and desferoxamine on distraction osteogenesis. Injury. 2022;53(6):1854-1857. [66] LIU Y, LIU J, CAI F, et al. Hypoxia during the consolidation phase of distraction osteogenesis promotes bone regeneration. Front Physiol. 2022;13:804469. [67] LIU J, KANG H, LU J, et al. Experimental study of the effects of hypoxia simulator on osteointegration of titanium prosthesis in osteoporotic rats. BMC Musculoskelet Disord. 2021;22(1):944. [68] YU Y, RAN Q, SHEN X, et al. Enzyme responsive titanium substrates with antibacterial property and osteo/angio-genic differentiation potentials. Colloids Surf B Biointerfaces. 2020;185:110592. [69] GUZEY S, AYKAN A, OZTURK S, et al. The effects of desferroxamine on bone and bone graft healing in critical-size bone defects. Ann Plast Surg. 2016;77(5):560-568. [70] XUN X, QIU J, ZHANG J, et al. Triple-functional injectable liposome-hydrogel composite enhances bacteriostasis and osteo/angio-genesis for advanced maxillary sinus floor augmentation. Colloids Surf B Biointerfaces. 2022;217:112706. [71] WAN C, GILBERT SR, WANG Y, et al. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A. 2008;105(2):686-691. [72] QU ZH, ZHANG XL, TANG TT, et al. Promotion of osteogenesis through beta-catenin signaling by desferrioxamine. Biochem Biophys Res Commun. 2008;370(2):332-337. [73] CHEN B, YAN YL, LIU C, et al. Therapeutic effect of deferoxamine on iron overload-induced inhibition of osteogenesis in a zebrafish model. Calcif Tissue Int. 2014; 94(3):353-360. [74] KUCHLER U, KEIBL C, FUGL A, et al. Dimethyloxalylglycine lyophilized onto bone substitutes increase vessel area in rat calvarial defects. Clin Oral Implants Res. 2015;26(5):485-491. [75] ZHANG W, LI G, DENG R, et al. New bone formation in a true bone ceramic scaffold loaded with desferrioxamine in the treatment of segmental bone defect: a preliminary study. J Orthop Sci. 2012;17(3):289-298. [76] LI Z, LI S, YANG J, et al. 3D bioprinted gelatin/gellan gum-based scaffold with double-crosslinking network for vascularized bone regeneration. Carbohydr Polym. 2022;290:119469. [77] HAN X, SUN M, CHEN B, et al. Lotus seedpod-inspired internal vascularized 3D printed scaffold for bone tissue repair. Bioact Mater. 2021;6(6):1639-1652. [78] FAN Z, LIU H, SHI S, et al. Anisotropic silk nanofiber layers as regulators of angiogenesis for optimized bone regeneration. Mater Today Bio. 2022;15:100283. [79] GENG M, ZHANG Q, GU J, et al. Construction of a nanofiber network within 3D printed scaffolds for vascularized bone regeneration. Biomater Sci. 2021;9(7):2631-2646. [80] XU D, GAN K, WANG Y, et al. A composite deferoxamine/black phosphorus nanosheet/gelatin hydrogel scaffold for ischemic tibial bone repair. Int J Nanomedicine. 2022;17:1015-1030. [81] JIA P, CHEN H, KANG H, et al. Deferoxamine released from poly(lactic-co-glycolic acid) promotes healing of osteoporotic bone defect via enhanced angiogenesis and osteogenesis. J Biomed Mater Res A. 2016;104(10):2515-2527. [82] WEI S, ZHANG RG, WANG ZY. Deferoxamine/magnesium modified beta-tricalcium phosphate promotes the bone regeneration in osteoporotic rats. J Biomater Appl. 2022;37(5):838-849. [83] DONNEYS A, YANG Q, FORREST ML, et al. Implantable hyaluronic acid-deferoxamine conjugate prevents nonunions through stimulation of neovascularization. NPJ Regen Med. 2019;4:11. [84] XING D, ZUO W, CHEN J, et al. Spatial delivery of triple functional nanoparticles via an extracellular matrix-mimicking coaxial scaffold synergistically enhancing bone regeneration. ACS Appl Mater Interfaces. 2022;14(33):37380-37395. [85] ZHANG J, TONG D, SONG H, et al. Osteoimmunity-regulating biomimetically hierarchical scaffold for augmented bone regeneration. Adv Mater. 2022;34(36):e2202044. [86] LIU K, LI L, CHEN J, et al. Bone ECM-like 3D printing scaffold with liquid crystalline and viscoelastic microenvironment for bone regeneration. ACS Nano. 2022;16(12):21020-21035. [87] ZHAO Y, CHEN H, RAN K, et al. Porous hydroxyapatite scaffold orchestrated with bioactive coatings for rapid bone repair. Biomater Adv. 2023;144:213202. [88] LI Z, CHENG S, LI A, et al. Fabrication of BMP-2-peptide-Deferoxamine- and QK-peptide-functionalized nanoscaffolds and their application for bone defect treatment. J Tissue Eng Regen Med. 2022;16(12):1223-1237. |
[1] | 杨玉芳, 杨芷姗, 段棉棉, 刘毅恒, 唐正龙, 王 宇. 促红细胞生成素在骨组织工程中的应用及前景[J]. 中国组织工程研究, 2024, 28(9): 1443-1449. |
[2] | 王姗姗, 舒 晴, 田 峻. 物理因子促进干细胞的成骨分化[J]. 中国组织工程研究, 2024, 28(7): 1083-1090. |
[3] | 尹 彤, 杨吉垒, 李友瑞, 刘卓冉, 姜 明. 核壳结构纳米纤维在口腔组织再生中的应用[J]. 中国组织工程研究, 2024, 28(5): 766-770. |
[4] | 王业元, 杜易朗, 于德浩, 宁凤婷, 白 冰. 微弧氧化处理对医用金属生物活性的影响[J]. 中国组织工程研究, 2024, 28(5): 771-776. |
[5] | 王嘉旎, 陈俊宇. 金属离子促血管生成机制及在骨组织工程中的应用[J]. 中国组织工程研究, 2024, 28(5): 804-812. |
[6] | 张 娅, 牟秋菊, 王自林, 刘宏杰, 祝丽丽. 负载富血小板血浆的水凝胶促进糖尿病大鼠创面愈合[J]. 中国组织工程研究, 2024, 28(5): 690-696. |
[7] | 朱礼威, 王江玥, 白 丁. 纳米复合甲基丙烯酰明胶水凝胶在不同骨缺损环境中应用的价值[J]. 中国组织工程研究, 2024, 28(5): 753-758. |
[8] | 杨雨晴, 陈志宇. 早期短暂M1巨噬细胞在骨组织工程中的作用及应用[J]. 中国组织工程研究, 2024, 28(4): 594-601. |
[9] | 高雪钰, 张文涛, 孙天泽, 张 警, 李忠海. 金属离子在骨组织工程中的应用[J]. 中国组织工程研究, 2024, 28(3): 439-444. |
[10] | 陈品叡, 裴锡波, 薛轶元. 磁响应水凝胶在骨组织工程中的作用与优势[J]. 中国组织工程研究, 2024, 28(3): 452-457. |
[11] | 龙智睿, 黄 雷, 肖 放, 王 琳, 王晓蓓. 骨组织工程中研究水凝胶微球的特征[J]. 中国组织工程研究, 2024, 28(3): 472-478. |
[12] | 徐 静, 吕慧欣, 鲍 鑫, 张 逸, 王一涵, 周延民. 近红外光响应水凝胶在组织工程领域的应用[J]. 中国组织工程研究, 2024, 28(3): 486-492. |
[13] | 董心雨, 董馨月, 王婉婷, 范海霞, 程焕芝. 中药有效成分结合支架材料促进骨组织再生[J]. 中国组织工程研究, 2024, 28(20): 3240-3245. |
[14] | 田 艾, 李 丽, 肖天骄, 康佳兵, 湛济帆, 韦 艳, 陈河林. 甲磺酸去铁胺促进去势骨质疏松大鼠颌骨缺损的修复[J]. 中国组织工程研究, 2024, 28(20): 3143-3149. |
[15] | 潘成镇, 陈 锋, 林宗汉, 莫 坚, 张 驰, 韦沅汛, 韦宗波. 萜类中药单体调控核转录因子κB信号通路防治骨质疏松症的机制[J]. 中国组织工程研究, 2024, 28(14): 2234-2241. |
1.1.7 检索策略 见图1。
1.1.8 检索文献量 初步纳入英文文献232篇,中文文献61篇,共293篇文献。
1.3 文献质量评估和数据的提取 通过中英文数据库检索共获取293篇文献,包括英文文献232篇及中文文献61篇。去除不同数据库中重复文献,阅读文献题目和摘要后去除内容不符文献,阅读全文排除研究不严谨文献,最终纳入文献88篇。文献筛选流程见图2。
#br#
文题释义:
去铁胺:是一种被美国食品和药物管理局批准的铁络合剂,属羟肟酸络合剂。在体内,去铁胺的羟肟酸基团对三价铁离子具有高亲和力并形成水溶性铁胺复合物后主要由尿排出,常用于铁超载或铁中毒的临床治疗。去铁胺作为一种铁络合剂被熟知,学者们利用其模拟低氧及稳定缺氧诱导因子1α的特性、通过单纯溶液注射或载药生物支架植入的方式将去铁胺应用于骨组织工程中研究其骨再生效应。研究显示,去铁胺还具有干细胞调节、抗炎抗氧化、成血管、成骨、抗破骨等骨再生相关特性,这些特性使去铁胺在骨折、骨坏死、牵张成骨、骨移植、口腔相关成骨及骨缺损中表现出巨大潜力的同时也存在优缺点,其应用方式和剂量应优化以实现更有效的骨再生。
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||